Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19242278 | CLINICAL DRESSING LOADED WITH COFFEE EXTRACT | June 2025 | January 2026 | Allow | 7 | 1 | 0 | No | No |
| 19241614 | CLINICAL DRESSING LOADED WITH COFFEE EXTRACT | June 2025 | February 2026 | Allow | 8 | 1 | 0 | No | No |
| 18826102 | MODIFICATION OF NATURAL COMPOUNDS TO CREATE PRODUCTS WITH ENHANCED HEALTH BENEFITS | September 2024 | June 2025 | Allow | 9 | 1 | 1 | Yes | No |
| 18745674 | COMPOSITIONS AND METHOD FOR TREATING AND PREVENTING COMPLICATIONS OF OBESITY | June 2024 | April 2025 | Allow | 10 | 1 | 1 | No | No |
| 18679420 | CLINICAL DRESSING LOADED WITH COFFEE EXTRACT | May 2024 | June 2025 | Allow | 12 | 1 | 1 | No | No |
| 18234592 | STABLE VITAMIN C COMPOSITIONS | August 2023 | January 2026 | Allow | 29 | 1 | 1 | No | No |
| 18232767 | FORMULATIONS CONTAINING OMEGA-3 FATTY ACIDS OR ESTERS THEREOF AND MAQUI BERRY EXTRACT AND THERAPEUTIC USES THEREOF | August 2023 | November 2025 | Abandon | 27 | 1 | 0 | No | No |
| 18353570 | COMPOSITIONS AND METHODS FOR IMPROVING MITOCHONDRIAL FUNCTION AND TREATING NEURODEGENERATIVE DISEASES AND COGNITIVE DISORDERS | July 2023 | March 2025 | Allow | 20 | 1 | 1 | No | No |
| 18345075 | METHODS AND COMPOSITIONS WITH PURIFIED BOMBYX MORI COCOON SILK PEPTIDE FIBER AND REFINED BUGLOSSOIDES ARVENSIS SEED OIL PROVIDING ANTI-INFLAMMATORY EFFECTS AND NEUROPROTECTION FOR DISEASE STATES | June 2023 | September 2024 | Allow | 14 | 1 | 0 | No | No |
| 18259881 | METHODS FOR ENHANCING MUSCLE PERFORMANCE OR REDUCING CHRONIC FATIGUE BY ADMINISTERING BOVINE MILK-DERIVED EXOSOMES | June 2023 | March 2026 | Abandon | 33 | 0 | 1 | No | No |
| 18205436 | COMPOSITION FOR PREVENTING OR TREATING SLEEP DISORDERS, CONTAINING ENZYME-TREATED ASHWAGANDHA EXTRACT AS ACTIVE INGREDIENT | June 2023 | October 2025 | Allow | 28 | 2 | 0 | Yes | No |
| 18203772 | Method for Synthesizing a Silver Nanoparticle Composition from Rhynchophorus ferrugineus Larvae Olivier | May 2023 | September 2024 | Allow | 16 | 2 | 0 | No | No |
| 18324829 | COMPOSITIONS AND METHODS FOR IMPROVING GUT HEALTH | May 2023 | December 2025 | Allow | 31 | 1 | 0 | No | No |
| 18185991 | COMPOSITION | March 2023 | January 2026 | Abandon | 34 | 1 | 1 | No | No |
| 18121471 | WATER-BASED INSECT REPELLENT COMPOSITION | March 2023 | January 2025 | Allow | 22 | 2 | 0 | No | No |
| 18145278 | USE OF ADVANCED PLATELET-RICH FIBRIN IN PREPARING MEDICAMENT FOR TREATMENT OF DIABETIC FOOT ULCER | December 2022 | March 2026 | Abandon | 39 | 1 | 1 | No | No |
| 18080825 | COMPOSITION FOR ENHANCING COGNITIVE ABILITIES AND USE THEREOF | December 2022 | December 2025 | Abandon | 36 | 1 | 0 | No | No |
| 18070078 | COMPOSITION FOR PREVENTING OR TREATING SLEEP DISORDERS, CONTAINING ENZYME-TREATED ASHWAGANDHA EXTRACT AS ACTIVE INGREDIENT | November 2022 | October 2023 | Abandon | 10 | 1 | 0 | No | No |
| 17951917 | TERPENE-CONTAINING COMPOSITIONS | September 2022 | March 2024 | Abandon | 17 | 0 | 1 | No | No |
| 17934408 | NOVEL COMPOSITION | September 2022 | October 2025 | Abandon | 37 | 2 | 1 | No | No |
| 17912592 | COMPOSITION FOR TREATMENT AND PREVENTION OF INFLAMMATORY DISEASES COMPRISING COMPOSITE EXTRACT OF BEET, RED ONION AND PURPLE SWEET POTATO AS ACTIVE INGREDIENTS | September 2022 | August 2025 | Abandon | 35 | 1 | 0 | No | No |
| 17880086 | METHOD FOR DEODORIZING KONJAC TUBER EXTRACT OR KONJAC TOBIKO CONTAINING GLUCOSYLCERAMIDE | August 2022 | October 2024 | Allow | 26 | 2 | 0 | Yes | No |
| 17865943 | COMPOSITIONS FOR CONTROLLING ARTHROPODS | July 2022 | August 2025 | Abandon | 37 | 2 | 1 | No | No |
| 17852803 | POMEGRANATE OIL FOR PREVENTING AND TREATING NEURODEGENERATIVE DISEASES | June 2022 | May 2025 | Allow | 35 | 2 | 0 | No | No |
| 17841323 | METHANOL-BASED EXTRACTION OF PSYCHOACTIVE ALKALOIDS FROM FUNGUS | June 2022 | January 2025 | Allow | 31 | 3 | 1 | No | Yes |
| 17836897 | WATER-BASED INSECT REPELLENT COMPOSITION | June 2022 | January 2023 | Allow | 8 | 1 | 1 | Yes | No |
| 17663932 | NATURAL PEST REPELLANT FORMULATIONS AND METHODS OF USE | May 2022 | April 2024 | Abandon | 23 | 0 | 1 | No | No |
| 17733623 | COMPOSITION FOR IMPROVED ENERGY, FOCUS AND CLARITY | April 2022 | August 2024 | Abandon | 28 | 1 | 1 | No | No |
| 17721343 | METHODS AND COMPOSITIONS WITH PURIFIED BOMBYX MORI COCOON SILK PEPTIDE FIBER AND REFINED BUGLOSSOIDES ARVENSIS SEED OIL PROVIDING ANTI-INFLAMMATORY EFFECTS AND NEUROPROTECTION FOR DISEASE STATES | April 2022 | April 2023 | Allow | 12 | 1 | 1 | Yes | No |
| 17716525 | ORAL SUPPLEMENTS CONTAINING ENRICHED PHENOLIC COMPOUND EXTRACTS COMBINED WITH ORGANIC ACID SODIUM SALTS, CREATINES AND/OR CREATINE SALTS | April 2022 | June 2025 | Allow | 38 | 2 | 1 | Yes | No |
| 17699348 | COMPOSITION COMPRISING PRUNUS PERSICA EXTRACT | March 2022 | April 2024 | Abandon | 24 | 1 | 0 | No | No |
| 17642645 | COMPOSITIONS COMPRISING NATURAL EXTRACTS FOR STIMULATING THE IMMUNE RESPONSE | March 2022 | April 2024 | Abandon | 25 | 2 | 1 | No | No |
| 17690506 | METHODS, ANHYDROUS COMPOSITIONS AND APPLICATORS FOR DELIVERY OF NUTRITIONAL SUPPLEMENTS WHILE CONCURRENTLY/SIMULTANEOUSLY PROVIDING AROMATHERAPY | March 2022 | May 2024 | Abandon | 27 | 0 | 1 | No | No |
| 17690028 | Pharmaceutical Composition for Treating Oral Ulcer and Preparation Method and Application Thereof | March 2022 | August 2023 | Allow | 17 | 0 | 0 | No | No |
| 17652432 | PROMOTION OF LYMPHATIC FUNCTION | February 2022 | January 2024 | Allow | 23 | 0 | 1 | No | No |
| 17679355 | MATERIALS AND METHODS FOR BLOCKING MALARIA INFECTION AND TRANSMISSION | February 2022 | May 2023 | Abandon | 14 | 1 | 1 | No | No |
| 17669581 | NUTRITIONAL FORMULATION FOR CANCER PREVENTION | February 2022 | March 2024 | Abandon | 25 | 0 | 1 | No | No |
| 17634364 | SKIN-CARE COMPOSITIONS AND USES THEREOF | February 2022 | May 2025 | Abandon | 39 | 0 | 1 | No | No |
| 17591838 | SPECIFIC NUTRITIONAL OR THERAPEUTIC AGENT INCLUDING A MIXTURE OF GRAPE AND BLUEBERRY | February 2022 | December 2024 | Allow | 34 | 1 | 1 | No | No |
| 17589746 | COMPOSITIONS AND METHODS FOR TREATING TRAVELER'S DIARRHEA | January 2022 | September 2024 | Allow | 32 | 1 | 1 | No | No |
| 17576922 | Compositions and Methods for Treating and Removing Seborrheic Keratoses | January 2022 | October 2023 | Allow | 21 | 1 | 1 | No | No |
| 17576502 | COMPOSITIONS AND METHODS FOR IMPROVING MITOCHONDRIAL FUNCTION AND TREATING NEURODEGENERATIVE DISEASES AND COGNITIVE DISORDERS | January 2022 | March 2024 | Allow | 26 | 1 | 1 | No | No |
| 17573783 | COMPOSITION FOR STRENGTHENING SKIN BARRIER OR MOISTURIZING SKIN COMPRISING TILIANIN | January 2022 | November 2024 | Abandon | 34 | 2 | 1 | No | No |
| 17626707 | METHODS FOR ISOLATING ESSENTIAL OILS, PHYTOCHEMICALS AND PHARMACEUTICALLY ACTIVE COMPONENTS FROM BIOMASS AND RECONSTITUTING SYNTHETIC FORMULATIONS COMPRISING SAME | January 2022 | May 2025 | Abandon | 40 | 0 | 1 | No | No |
| 17573060 | NUTRACEUTICAL FORMULATION FOR UNBLOCKING RECEPTORS | January 2022 | March 2025 | Abandon | 38 | 0 | 1 | No | No |
| 17565948 | DIAPER CREAM | December 2021 | December 2025 | Allow | 47 | 3 | 1 | Yes | No |
| 17537858 | METHOD FOR TREATING OR PREVENTING INFLAMMATION | November 2021 | June 2024 | Abandon | 30 | 2 | 0 | No | No |
| 17613522 | MODIFIED BLACK SOLDIER FLY LARVAE OIL WITH MODIFIED LAURIC ACID FOR TREATMENT AGAINST BIOFILM FORMATION AND MICROORGANISM GROWTH | November 2021 | March 2025 | Abandon | 40 | 0 | 1 | No | No |
| 17533211 | METHOD OF PREVENTING AND TREATING NEURODEGENERATIVE DISORDERS USING SOPHORA JAPONICA L. EXTRACT AS ACTIVE INGREDIENT | November 2021 | August 2025 | Abandon | 45 | 3 | 1 | No | No |
| 17610507 | COMPOSITIONS COMPRISING PLANT EXTRACTS AND OILS AND RELATED METHODS OF TREATMENT AND THEIR PREPARATION | November 2021 | March 2025 | Abandon | 40 | 0 | 1 | No | No |
| 17521679 | METHODS FOR REDUCING NEGATIVE EFFECTS OF ALCOHOL CONSUMPTION | November 2021 | September 2025 | Abandon | 47 | 3 | 1 | No | No |
| 17519859 | METHODS FOR OPTIMIZED CANNABINOID DOSAGE DETERMINATION | November 2021 | March 2025 | Abandon | 40 | 0 | 1 | No | No |
| 17518799 | ANTIDIABETIC COMPOSITION COMPRISING GINGER EXTRACT OBTAINED FROM MICROWAVE-PROCESSED GINGER AND METHOD OF PREVENTING OR TREATING DIABETIS MELLITUS | November 2021 | November 2024 | Abandon | 36 | 2 | 1 | No | No |
| 17608490 | MAQUI BERRY EXTRACTS FOR TREATMENT OF SKIN DISEASES | November 2021 | October 2025 | Allow | 48 | 1 | 1 | No | No |
| 17506680 | HERBAL CONFECTIONERY CANDY FOR EYESIGHT IMPROVING | October 2021 | May 2023 | Abandon | 19 | 2 | 1 | No | No |
| 17502531 | HEMP AND PEA FORMULATION AND ITS USE | October 2021 | June 2025 | Allow | 44 | 1 | 1 | Yes | No |
| 17501309 | COMPOUND FOR TREATING OXIDATIVE STRESS IN MAMMALS | October 2021 | June 2022 | Allow | 8 | 1 | 1 | No | No |
| 17432327 | PRODUCTION PROMOTER OF TYPE I COLLAGEN OR ELASTIN | August 2021 | July 2025 | Abandon | 47 | 2 | 0 | Yes | No |
| 17400409 | COMPOSITIONS AND METHOD FOR TREATING AND PREVENTING COMPLICATIONS OF OBESITY | August 2021 | February 2024 | Allow | 30 | 5 | 1 | Yes | No |
| 17428968 | CANNABINOID CONTAINING COMPOSITION, METHODS OF PREPARATION AND USE THEREOF | August 2021 | August 2025 | Abandon | 48 | 1 | 1 | No | No |
| 17380787 | METHODS AND COMPOUND FOR THE TREATMENT OF MALARIA | July 2021 | May 2024 | Abandon | 34 | 1 | 0 | No | No |
| 17379804 | DEVICES AND METHODS FOR TREATING EAR PAIN | July 2021 | February 2024 | Allow | 31 | 1 | 1 | No | No |
| 17375715 | ANTIBACTERIAL AND ANTIVIRUS COMPOSITION COMPRISING Extract of CANNABIS SATIVA L. | July 2021 | June 2024 | Abandon | 35 | 2 | 1 | No | No |
| 17370994 | USE OF GRAPE AND/OR SOY SUPPLEMENTS AGAINST COVID-19 AND 92 OTHER VIRUSES AND BACTERIA INCLUDING OTHER UNKNOWN VIRUSES AND BACTERIA | July 2021 | February 2024 | Abandon | 31 | 1 | 0 | No | No |
| 17368410 | SEBUM CONTROL AND ANTI-ACNE COMPOSITION | July 2021 | May 2025 | Abandon | 46 | 2 | 0 | Yes | No |
| 17417061 | CANNABINOID FORMULATIONS AND METHODS OF MAKING SAME | June 2021 | August 2025 | Abandon | 50 | 1 | 1 | No | No |
| 17351621 | Cannabinoid-Containing Composition | June 2021 | September 2024 | Abandon | 39 | 0 | 1 | No | No |
| 17334016 | Hair Growth Compositions | May 2021 | June 2024 | Abandon | 37 | 2 | 1 | No | No |
| 17332778 | COMPOSITIONS AND METHODS FOR TREATING COVID-19 INFECTIONS WITH AN EXTRACT OF DICHROSTACHYS GLOMERATA | May 2021 | June 2024 | Allow | 37 | 2 | 0 | Yes | No |
| 17297299 | METHOD FOR PRODUCING RED PERILLA LEAF EXTRACT | May 2021 | October 2024 | Abandon | 41 | 1 | 0 | No | No |
| 17240947 | DEVICES AND METHODS FOR PROMOTING DRAINAGE OF FLUID FROM A EUSTACHIAN TUBE | April 2021 | May 2025 | Allow | 49 | 3 | 0 | No | Yes |
| 17239083 | CONTROLLED DECARBOXYLATION OF ACTIVE COMPOUNDS | April 2021 | August 2024 | Abandon | 40 | 0 | 1 | No | No |
| 17207339 | COMPOUND FOR TREATING OXIDATIVE STRESS IN CANINES | March 2021 | December 2022 | Allow | 21 | 3 | 1 | No | No |
| 17204245 | COMPOSITION INCLUDING LACTIC ACID BACTERIAL STRAIN AND HERBAL EXTRACT FOR PROMOTING DEFECATION | March 2021 | October 2023 | Allow | 31 | 2 | 1 | No | No |
| 17276146 | USE OF NUCIFERIN AND LOTUS LEAF EXTRACT IN THE PREPARATION OF A MEDICAMENT FOR TREATING ATROPHIC GASTRITIS AND/OR BLOCKING TRANSFORMATION OF GASTRITIS INTO CANCER | March 2021 | December 2024 | Abandon | 46 | 4 | 1 | No | Yes |
| 17198102 | EDIBLE, SINGLE-EXTRACTION CURCUMA EXTRACTS | March 2021 | April 2024 | Allow | 37 | 1 | 1 | No | No |
| 17273917 | INFLAMMATORY CYTOKINE PRODUCTION INHIBITOR | March 2021 | September 2025 | Abandon | 55 | 2 | 0 | No | No |
| 17260891 | INFLAMMATORY CYTOKINE PRODUCTION INHIBITOR | March 2021 | July 2024 | Abandon | 41 | 2 | 0 | No | No |
| 17179447 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CORONAVIRUS INFECTION | February 2021 | September 2022 | Allow | 19 | 3 | 1 | Yes | No |
| 17169666 | DISCOVERY OF POTENT [ALPHA]-GLUCOSIDASE INHIBITORS FROM HETEROPHRAGMA ADENOPHYLLUM | February 2021 | August 2022 | Allow | 18 | 4 | 1 | No | No |
| 17266760 | FORMULATIONS CONTAINING LIPOPHILIC EXTRACTS OF SPICY EDIBLE PLANTS USEFUL IN CONTROLLING PAIN AND INFLAMMATION | February 2021 | December 2023 | Abandon | 35 | 1 | 1 | No | No |
| 17168483 | HERBAL SUPPLEMENTS AND METHODS OF USE THEREOF | February 2021 | December 2023 | Allow | 34 | 1 | 1 | No | No |
| 17143757 | STABLE VITAMIN C COMPOSITIONS | January 2021 | May 2023 | Allow | 28 | 1 | 1 | No | No |
| 17257229 | LIPID EMULSION FOR PARENTERAL ADMINISTRATION | December 2020 | January 2026 | Allow | 60 | 5 | 1 | Yes | No |
| 17251027 | COMPOSITION FOR IMPROVING INTESTINAL FLORA | December 2020 | March 2024 | Abandon | 40 | 2 | 1 | Yes | No |
| 17114217 | COMPOUND FOR TREATING OXIDATIVE STRESS IN MAMMALS | December 2020 | April 2022 | Abandon | 17 | 2 | 1 | No | No |
| 17105628 | ANTIDEPRESSANT COMPOUND PREPARATION AND PREPARATION METHOD THEREOF | November 2020 | January 2023 | Allow | 25 | 0 | 1 | No | No |
| 17056887 | ANGIOTENSIN I-CONVERTING ENZYME ACTIVITY INHIBITOR | November 2020 | February 2023 | Abandon | 27 | 1 | 0 | No | No |
| 17054764 | COMPOSITION COMPRISING CLEMATIS MANDSHURICA EXTRACT AS ACTIVE INGREDIENT FOR COGNITIVE FUNCTION IMPROVEMENT | November 2020 | March 2024 | Abandon | 41 | 3 | 1 | No | No |
| 17067489 | COMPOSITIONS WITH PURIFIED BOMBYX MORI COCOON SILK PEPTIDE FIBER AND REFINED BUGLOSSOIDES ARVENSIS SEED OIL HAVING SYNERGISTIC EFFECTS FOR IMPROVING MEMORY, FOCUS, AND COGNITIVE FUNCTION, AND RELATED METHODS | October 2020 | March 2022 | Allow | 18 | 1 | 1 | Yes | No |
| 17043737 | TRADITIONAL CHINESE MEDICINE EXTRACT COMPOSITION WITH FUNCTION OF REGULATING DEPRESSIVE EMOTION AND PREPARATION METHOD AND TRADITIONAL CHINESE MEDICINE PREPARATION THEREOF | September 2020 | December 2024 | Abandon | 51 | 1 | 1 | No | No |
| 17042263 | RETINOL REPLACEMENT IN SKIN TREATMENT | September 2020 | June 2023 | Allow | 32 | 2 | 1 | Yes | No |
| 17002265 | METHODS FOR EXTRACTION OF MELANIN FROM FUNGAL SPECIES | August 2020 | February 2024 | Abandon | 42 | 2 | 1 | No | No |
| 17002461 | HERBAL FORMULATIONS OF CARNIVOROUS PLANTS AND METHODS FOR TREATING INFLAMMATION | August 2020 | January 2025 | Allow | 53 | 2 | 1 | No | No |
| 16967857 | COMPOSITION FOR THE PREVENTION AND TREATMENT OF DISEASES OF THE RESPIRATORY TRACT | August 2020 | August 2024 | Abandon | 49 | 2 | 1 | No | No |
| 16928200 | Compositions and Methods for Improving Mitochondrial Function and Treating Neurodegenerative Diseases and Cognitive Disorders | July 2020 | October 2023 | Allow | 39 | 1 | 1 | No | No |
| 16895990 | COMPOSITIONS CONTAINING NATURAL EXTRACTS AND USE THEREOF FOR SKIN AND HAIR | June 2020 | November 2022 | Abandon | 30 | 0 | 1 | No | No |
| 16882741 | EXTRACT EFFECTIVE IN TREATING DRUG ADDICTION | May 2020 | January 2024 | Allow | 44 | 4 | 1 | No | No |
| 16763854 | COMPOSITIONS INCLUDING PINE BARK EXTRACT, BERRYFRUIT EXTRACT AND A SOURCE OF L-THEANINE AND USES THEREOF | May 2020 | October 2025 | Allow | 60 | 3 | 1 | Yes | No |
| 16838661 | PRESERVATIVE COMPOSITION | April 2020 | July 2022 | Abandon | 28 | 1 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner CHEN, CATHERYNE.
With a 20.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 36.4% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is above the USPTO average, suggesting that filing an appeal can be an effective strategy for prompting reconsideration.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
Examiner CHEN, CATHERYNE works in Art Unit 1655 and has examined 891 patent applications in our dataset. With an allowance rate of 32.8%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 43 months.
Examiner CHEN, CATHERYNE's allowance rate of 32.8% places them in the 5% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by CHEN, CATHERYNE receive 2.38 office actions before reaching final disposition. This places the examiner in the 68% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by CHEN, CATHERYNE is 43 months. This places the examiner in the 16% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +20.9% benefit to allowance rate for applications examined by CHEN, CATHERYNE. This interview benefit is in the 65% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.
When applicants file an RCE with this examiner, 14.0% of applications are subsequently allowed. This success rate is in the 9% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 23.2% of cases where such amendments are filed. This entry rate is in the 31% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
When applicants request a pre-appeal conference (PAC) with this examiner, 147.4% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 89% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.
This examiner withdraws rejections or reopens prosecution in 93.5% of appeals filed. This is in the 85% percentile among all examiners. Of these withdrawals, 62.5% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 75.3% are granted (fully or in part). This grant rate is in the 81% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 3.8% of allowed cases (in the 82% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 2% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.